DK1599216T3 - Fremgangsmåde til forebyggelse af mitokondriel permeabilitets-transition - Google Patents

Fremgangsmåde til forebyggelse af mitokondriel permeabilitets-transition

Info

Publication number
DK1599216T3
DK1599216T3 DK04707809.2T DK04707809T DK1599216T3 DK 1599216 T3 DK1599216 T3 DK 1599216T3 DK 04707809 T DK04707809 T DK 04707809T DK 1599216 T3 DK1599216 T3 DK 1599216T3
Authority
DK
Denmark
Prior art keywords
net positive
mitochondrial permeability
minimum
preventing mitochondrial
permeability transition
Prior art date
Application number
DK04707809.2T
Other languages
Danish (da)
English (en)
Inventor
Hazel H Szeto
Kesheng Zhao
Peter W Schiller
Original Assignee
Cornell Res Foundation Inc
Clinical Res Inst Of Montreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Res Foundation Inc, Clinical Res Inst Of Montreal filed Critical Cornell Res Foundation Inc
Application granted granted Critical
Publication of DK1599216T3 publication Critical patent/DK1599216T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
DK04707809.2T 2003-02-04 2004-02-03 Fremgangsmåde til forebyggelse af mitokondriel permeabilitets-transition DK1599216T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44477703P 2003-02-04 2003-02-04
US53569004P 2004-01-08 2004-01-08
PCT/US2004/003193 WO2004070054A2 (en) 2003-02-04 2004-02-03 Methods for preventing mitochondrial permeability transition

Publications (1)

Publication Number Publication Date
DK1599216T3 true DK1599216T3 (da) 2013-12-09

Family

ID=32853391

Family Applications (3)

Application Number Title Priority Date Filing Date
DK04707809.2T DK1599216T3 (da) 2003-02-04 2004-02-03 Fremgangsmåde til forebyggelse af mitokondriel permeabilitets-transition
DK13178043.9T DK2656854T3 (en) 2003-02-04 2004-02-03 Applications of an aromatic-cationic peptide
DK14186875.2T DK2865385T3 (en) 2003-02-04 2004-02-03 Applications of the aromatic-cationic peptide

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK13178043.9T DK2656854T3 (en) 2003-02-04 2004-02-03 Applications of an aromatic-cationic peptide
DK14186875.2T DK2865385T3 (en) 2003-02-04 2004-02-03 Applications of the aromatic-cationic peptide

Country Status (13)

Country Link
US (8) US7576061B2 (enExample)
EP (9) EP3659618A1 (enExample)
JP (7) JP4838114B2 (enExample)
CN (3) CN102784383B (enExample)
AU (1) AU2004209663B2 (enExample)
CA (1) CA2515080C (enExample)
CY (2) CY1114959T1 (enExample)
DK (3) DK1599216T3 (enExample)
ES (3) ES2436011T3 (enExample)
HU (1) HUE027110T2 (enExample)
PT (2) PT1599216E (enExample)
SI (1) SI2656854T1 (enExample)
WO (1) WO2004070054A2 (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2436011T3 (es) 2003-02-04 2013-12-26 Cornell Research Foundation, Inc. Métodos para prevenir la transición de la permeabilidad mitocondrial
CN100506841C (zh) 2003-05-01 2009-07-01 科内尔研究基金会 将分子递送到细胞的方法和载体复合物
RU2376028C2 (ru) * 2004-01-23 2009-12-20 Корнелл Рисеч Фаундейшн, Инк. Способ уменьшения окислительного повреждения (варианты)
CA2947330C (en) * 2005-09-16 2018-06-05 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
AU2014203126B2 (en) * 2005-09-16 2016-03-10 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
CA2713150C (en) 2008-02-07 2016-01-05 Cornell University Methods for preventing or treating insulin resistance
DK2262520T3 (en) 2008-02-26 2017-08-07 Univ Cornell COMPOSITIONS FOR PREVENTION AND TREATMENT OF Kidney Injury
DE102008061044A1 (de) * 2008-12-11 2010-06-17 Henkel Ag & Co. Kgaa Zusammensetzung mit antioxidativ wirksamen Peptiden
CN102573881A (zh) * 2009-03-20 2012-07-11 通用医疗公司以马萨诸塞州通用医疗公司名义经营 预防和治疗烧伤损伤和继发性并发症的方法
DK2464371T3 (en) * 2009-08-12 2016-06-27 Univ Cornell Methods for preventing or treating metabolic syndrome
WO2011025734A1 (en) * 2009-08-24 2011-03-03 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
EP2764871A1 (en) * 2009-10-05 2014-08-13 Cornell University Methods for the prevention or treatment of heart failure
US20130190244A1 (en) * 2009-12-31 2013-07-25 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
WO2011082324A1 (en) * 2009-12-31 2011-07-07 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
WO2011091357A1 (en) * 2010-01-25 2011-07-28 Cornell University Aromatic-cationic peptides and uses of same
EP3511012A1 (en) * 2010-02-26 2019-07-17 Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
EP2547352A4 (en) * 2010-03-15 2013-10-09 Stealth Peptides Int Inc COMBINATION THERAPIES USING CYCLOSPORINE AND AROMATIC CATIONIC PEPTIDES
US20110245183A1 (en) 2010-04-06 2011-10-06 Perricone Nicholas V Topical Uses of Szeto-Schiller Peptides
US20110245182A1 (en) 2010-04-06 2011-10-06 Perricone Nicholas V Topical Uses of Szeto-Schiller Peptides
EP3290433A1 (en) * 2010-05-03 2018-03-07 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
WO2014137496A1 (en) * 2013-03-08 2014-09-12 The Administrators Of The Tulane Educational Fund Mu opioid receptor agonist analogs of the endomorphins
JP6319738B2 (ja) * 2010-07-09 2018-05-09 ステルス ペプチドズ インターナショナル インコーポレイテッド 虚血／再灌流障害に続くノーリフローの予防又は処置方法
US20160176930A1 (en) 2010-07-09 2016-06-23 The Administrators Of The Tulane Educational Fund Mu opioid receptor agonist analogs of the endomorphins
US20120083452A1 (en) * 2010-09-30 2012-04-05 Perricone Nicholas V Topical Anesthetic Uses of Szeto-Schiller Peptides
EP2688579A4 (en) * 2011-03-24 2015-10-21 Univ Cornell CATIONIC AROMATIC PEPTIDES AND USES THEREOF
HK1200459A1 (en) * 2011-09-19 2015-08-07 Gencia Corporation Modified creatine compounds
WO2013049697A1 (en) 2011-09-29 2013-04-04 Mayo Foundation For Medical Education And Research Aromatic-cationic peptides and methods for using same
CA2852454A1 (en) * 2011-10-17 2013-04-25 Cornell University Aromatic-cationic peptides and uses of same
EP3466439A1 (en) 2011-12-09 2019-04-10 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
JP6317324B2 (ja) 2012-03-30 2018-04-25 ステルス ペプチドズ インターナショナル インコーポレイテッド 神経障害を予防および処置するための方法および組成物
JP2015524439A (ja) * 2012-08-02 2015-08-24 ステルス ペプチドズ インターナショナル インコーポレイテッド アテローム性硬化症の処置方法
ES3058737T3 (en) * 2012-10-22 2026-03-12 Stealth Biotherapeutics Inc Treatment of left ventricular remodeling
ES2750258T3 (es) * 2013-03-01 2020-03-25 Stealth Biotherapeutics Corp Métodos y composiciones para la prevención o tratamiento del síndrome de Barth
CN117752766A (zh) * 2013-03-01 2024-03-26 康德生物医疗有限公司 治疗线粒体疾病的方法
US9850278B2 (en) 2013-04-25 2017-12-26 Carmel-Haifa University Economic Corp. Synthetic anti-inflammatory peptides and use thereof
WO2014209905A2 (en) 2013-06-26 2014-12-31 Stealth Peptides International, Inc. Methods and compositions for detecting and diagnosing diseases and conditions
CA2919992C (en) * 2013-08-01 2022-08-09 Stealth Biotherapeutics Corp Methods and compositions for preventing or treating leber's hereditary optic neuropathy
US20160166633A1 (en) 2013-08-02 2016-06-16 Stealth Bio Therapeutics Corp Methods and compositions for the prevention and treatment of friedreich's ataxia
WO2015048647A1 (en) * 2013-09-30 2015-04-02 Cornell University Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity
EP3154694B1 (en) 2014-06-13 2025-01-29 Children's Medical Center Corporation Products and methods to isolate mitochondria
EP3160984B1 (en) 2014-06-25 2021-04-14 Flamma S.P.A. Process for preparing d-arginyl-2,6-dimethyl-l-tyrosyl-l-lysyl-l-phenylalaninamide
PL3160985T3 (pl) 2014-06-30 2021-12-27 Flamma S.P.A. Sposób wytwarzania d-arginylo-2,6-dimetylo-l-tyrozylo-l-lizylo-l-fenyloalaninoamidu
WO2016004093A2 (en) * 2014-07-01 2016-01-07 Stealth Biotherapeutics Corp Therapeutic compositions including galectin-3 inhibitors and uses thereof
CN104306954B (zh) * 2014-09-25 2016-08-24 中山大学 Wry三肽在制备治疗阿尔茨海默症药物中的用途
WO2016069556A2 (en) 2014-10-29 2016-05-06 University Of Maryland Methods of treating age-related symptoms in mammals and compositions therefor
WO2017015660A1 (en) * 2015-07-23 2017-01-26 Salk Institute For Biological Studies Prevention and treatment of aging and neurodegenerative diseases
WO2017093897A1 (en) * 2015-11-30 2017-06-08 Peter Schiller Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome
ES3057779T3 (en) 2016-01-15 2026-03-04 Childrens Medical Ct Corp Therapeutic use of mitochondria and combined mitochondrial agents
JP7038675B2 (ja) * 2016-03-11 2022-03-18 ステルス バイオセラピューティクス インコーポレイテッド 結晶塩形態
WO2017180535A1 (en) 2016-04-11 2017-10-19 Carnot, Llc Chiral peptides
WO2018100893A1 (ja) 2016-11-30 2018-06-07 株式会社ダイセル 撮像装置用レンズモジュール及びその製造方法
US11034724B2 (en) 2017-04-05 2021-06-15 Stealth Biotherapeutics Corp. Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2
EP3668837B1 (en) 2017-08-17 2022-07-06 XWPharma Ltd. Preparation and uses of reactive oxygen species scavenger derivatives
EP3988561B1 (en) 2017-09-04 2023-06-07 XWPharma Ltd. Preparation and use of reactive oxygen species scavenger
JP6958860B2 (ja) * 2017-11-07 2021-11-02 学校法人自治医科大学 ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
IL284006B2 (en) * 2018-12-18 2024-12-01 Stealth Biotherapeutics Corp Mitochondria-targeting peptides
WO2020222866A1 (en) * 2019-05-02 2020-11-05 Children's Medical Center Corporation Prophylactic and therapeutic use of mitochondria and combined mitochondrial agents
EP3771467A1 (en) 2019-07-30 2021-02-03 Fundacio Institut de Recerca de l'Hospital de la Santa Creu i sant Pau Ss-31 for the prevention and/or treatment of aneurysm
KR20240073137A (ko) * 2020-09-09 2024-05-24 소셜 프로핏 네트워크 미토콘드리아에 비오틴의 전달을 위한 방법 및 조성물
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP0350221B1 (en) 1988-06-30 1996-04-17 Astra Aktiebolag Dermorphin analogs, their methods of preparation, pharmaceutical compositions, and methods of therapeutic treatment using the same
US5602100A (en) 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
US5674980A (en) 1989-12-21 1997-10-07 Biogen Inc Fusion protein comprising tat-derived transport moiety
WO1991010361A1 (en) * 1990-01-17 1991-07-25 The Regents Of The University Of California Composition to improve survival of biological materials
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
IS4261A (is) 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra
EP0747092B1 (en) * 1995-06-09 2003-12-03 Hisamitsu Pharmaceutical Co., Inc. Matrix for iontophoresis
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
ATE240728T1 (de) * 1996-10-07 2003-06-15 Lilly Co Eli Neue verbindungen nutlich als neuroschützende mittel
US5885958A (en) 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
WO1999029721A1 (en) 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
US6268398B1 (en) * 1998-04-24 2001-07-31 Mitokor Compounds and methods for treating mitochondria-associated diseases
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
GB9905503D0 (en) * 1999-03-10 1999-05-05 Adprotech Plc Novel compound formulations and methods of delivery
SE9900961D0 (sv) 1999-03-16 1999-03-16 Astra Ab Novel compounds
WO2001025188A1 (en) * 1999-10-04 2001-04-12 University Of Medicine And Dentistry Of New Jersey Novel carbamates and ureas
US6759520B1 (en) * 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
CA2416475C (en) * 2000-07-18 2011-10-11 Cornell Research Foundation, Inc. Medicinal uses of mu-opioid receptor agonists
US6900178B2 (en) 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
JP2004523490A (ja) * 2000-11-28 2004-08-05 ギルフォード ファーマシュウティカルズ インコーポレイテッド 二置換カルボサイクリックサイクロフィリン結合化合物とその用途
US6545097B2 (en) * 2000-12-12 2003-04-08 Scimed Life Systems, Inc. Drug delivery compositions and medical devices containing block copolymer
MXPA03006666A (es) * 2001-01-25 2004-05-31 Guilford Pharm Inc Compuestos de union de ciclofilina carbociclicos trisubstituidos y su uso.
US20030077826A1 (en) * 2001-02-02 2003-04-24 Lena Edelman Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
US6942681B2 (en) * 2001-02-16 2005-09-13 Cordis Corporation Method of balloon catheter stent delivery system with ridges
JP2004526499A (ja) * 2001-03-16 2004-09-02 エスティーエス バイオポリマーズ，インコーポレイティド 複数層ポリマーコーティングを有する薬物添加ステント
WO2002102833A1 (fr) * 2001-06-15 2002-12-27 Senju Pharmaceutical Co., Ltd. Nouveaux derives d'endomorphine
ES2436011T3 (es) 2003-02-04 2013-12-26 Cornell Research Foundation, Inc. Métodos para prevenir la transición de la permeabilidad mitocondrial
CN100536909C (zh) * 2003-02-04 2009-09-09 科内尔研究基金会 用于防止线粒体通透性改变的方法
CN100506841C (zh) 2003-05-01 2009-07-01 科内尔研究基金会 将分子递送到细胞的方法和载体复合物
JP2005005762A (ja) * 2003-06-09 2005-01-06 Fujitsu Ltd 送信電力制御方法及び装置
US7232824B2 (en) 2003-09-30 2007-06-19 Scios, Inc. Quinazoline derivatives as medicaments
RU2376028C2 (ru) * 2004-01-23 2009-12-20 Корнелл Рисеч Фаундейшн, Инк. Способ уменьшения окислительного повреждения (варианты)
CA2947330C (en) 2005-09-16 2018-06-05 Cornell Research Foundation, Inc. Methods for reducing cd36 expression

Also Published As

Publication number Publication date
CN102617706A (zh) 2012-08-01
JP6166312B2 (ja) 2017-07-19
AU2004209663B2 (en) 2009-01-15
US20120021970A1 (en) 2012-01-26
ES2540897T3 (es) 2015-07-14
HK1190930A1 (en) 2014-07-18
JP2015180693A (ja) 2015-10-15
JP5775285B2 (ja) 2015-09-09
CN102784383B (zh) 2014-09-17
JP2015007127A (ja) 2015-01-15
PT2656854E (pt) 2015-09-03
WO2004070054A3 (en) 2005-04-14
US20150359838A1 (en) 2015-12-17
EP3659618A1 (en) 2020-06-03
EP1599216B1 (en) 2013-11-06
WO2004070054A2 (en) 2004-08-19
EP2656854A1 (en) 2013-10-30
EP2656854B1 (en) 2015-05-20
JP6126059B2 (ja) 2017-05-10
JP4838114B2 (ja) 2011-12-14
DK2656854T3 (en) 2015-07-06
US20130244957A1 (en) 2013-09-19
US20100190718A1 (en) 2010-07-29
JP2006516652A (ja) 2006-07-06
US20040248808A1 (en) 2004-12-09
DK2865385T3 (en) 2016-12-19
CY1116575T1 (el) 2017-03-15
SI2656854T1 (sl) 2015-09-30
CN102784383A (zh) 2012-11-21
HK1090571A1 (en) 2006-12-29
EP2865385A1 (en) 2015-04-29
EP2491943A2 (en) 2012-08-29
HK1131995A1 (en) 2010-02-12
JP5837542B2 (ja) 2015-12-24
US7576061B2 (en) 2009-08-18
CY1114959T1 (el) 2016-12-14
EP1599216A4 (en) 2009-11-11
CA2515080C (en) 2012-04-10
EP1599216A2 (en) 2005-11-30
JP2019089773A (ja) 2019-06-13
EP1599216B9 (en) 2015-02-11
ES2605504T3 (es) 2017-03-14
US20200038472A1 (en) 2020-02-06
AU2004209663A1 (en) 2004-08-19
EP3144009A1 (en) 2017-03-22
HK1209652A1 (en) 2016-04-08
JP2013249313A (ja) 2013-12-12
HUE027110T2 (en) 2016-08-29
ES2436011T3 (es) 2013-12-26
JP2011026346A (ja) 2011-02-10
EP3842055A1 (en) 2021-06-30
CN104225574A (zh) 2014-12-24
EP3479838A1 (en) 2019-05-08
US7718620B2 (en) 2010-05-18
US20070027087A1 (en) 2007-02-01
CN104225574B (zh) 2017-01-11
EP2865385B1 (en) 2016-11-16
PT1599216E (pt) 2013-12-17
CA2515080A1 (en) 2004-08-19
US8957030B2 (en) 2015-02-17
EP2491943B1 (en) 2018-10-10
HK1178794A1 (en) 2013-09-19
EP2491943A3 (en) 2013-01-23
HK1204999A1 (en) 2015-12-11
US8404646B2 (en) 2013-03-26
EP3305313A1 (en) 2018-04-11
JP2017095519A (ja) 2017-06-01
AU2004209663A2 (en) 2004-08-19
US20230293624A1 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
EP2491943A3 (en) Methods for preventing mitochondrial permeability transition
WO2005072295A3 (en) Methods for reducing oxidative damage
FI942005A7 (fi) Peptidianalogeja irreversiibeleinä interleukiini-1beta-proteaasi-inhibiittoreina
DE602005023315D1 (de) Antimikrobielle peptide mit einem arginin- und /oder lysin-haltigen motiv
ATE390441T1 (de) Niedrigallergene proteinvarianten
AU9315398A (en) Chemokine peptides, variants, derivatives and analogs. their use in methods to inhibit or augment an inflammatory response
AU3537293A (en) Synthetic polypeptides as inhibitors of HIV-1
ATE278710T1 (de) Antimikrobiell wirksame peptide
ATE421526T1 (de) Prodrugs von exzitatorischen aminosäuren
BR9408087A (pt) Recuperação de um aminoácido
ATE509886T1 (de) Peptidnanostrukturen, verfahren zu deren herstellung und verwendung
PT896615E (pt) Peptido proveniente de uma forma soluvel de acetilcolinesterase activo como modulador dos canais de calcio
BR0304562A (pt) Inibidor de gama-secretase
FR2653303B1 (fr) Agents edulcorants de grande stabilite derivant des acides l-aspartique et l-glutamique n-hydrocarbones 1-oxo-2-ramifies.
DE602004028266D1 (de) Angiogene peptide und ihre verwendungen
BR9711540A (pt) Inibidores de protease proteìnico estabilizados e variantes dos mesmos
FI925696A7 (fi) Hirudiinin aminohapposekvenssiin perustuvia trombiininestäjiä
DE60329115D1 (de) Tumorantigenprotein und dessen verwendung
ATE82984T1 (de) Hemmende peptide.
WO2003097677A3 (fr) Nouvelles compostions peptidiques et leur utilisation notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l'hepatite c
DK1474439T3 (da) Dipeptider og tripeptider med anti-inflammatorisk virkning
EP1572714A4 (en) VMP-Similar Sequences of Pathogenic Borrelia Species and Stem
ATE292682T1 (de) Serin-proteinase-inhibitoren
ITMI20020624A1 (it) Composizioni ad attivita' biostimolante
ATE281522T1 (de) Sentrin-spezifische menschliche protease senp1